Poor
Needs Review
Patient Risk:
Moderate
Summary
Substantial portions of the claims are not auditable because key label sections (especially 1 INDICATIONS AND USAGE and 14 CLINICAL STUDIES) are not provided, and several safety/tolerability and “common side effects” claims rely on non-equivalent label context (10 OVERDOSAGE used as basis for common adverse effects). Mechanism claims are only partially supported by the provided 12.1 excerpt.
Category Scores
Accurate Statements
Azacitidine (Vidaza) is a hypomethylating agent.
12.1 Mechanism of Action: 'causing hypomethylation of DNA'
Unsupported Statements
Azacitidine is approved for the treatment of myelodysplastic syndromes (MDS).
Label section 1 INDICATIONS AND USAGE was not provided, so approval for MDS cannot be verified against the supplied label text.
Azacitidine is approved for the treatment of acute myeloid leukemia (AML).
Label section 1 INDICATIONS AND USAGE was not provided, so approval for AML cannot be verified against the supplied label text.
Gene demethylation results in reactivation of silenced genes.
Not supported by the provided 12.1 excerpt.
Gene demethylation suppresses aberrant gene expression.
Not supported by the provided 12.1 excerpt.
A phase II trial found that azacitidine significantly reduced the incidence of severe GVHD.
14 CLINICAL STUDIES content was not provided, so this comparative efficacy/safety GVHD outcome cannot be verified.
A phase II trial found that azacitidine improved overall survival in patients with acute leukemia.
14 CLINICAL STUDIES content was not provided, so this overall survival claim cannot be verified.
Azacitidine is associated with a significant reduction in GVHD-related mortality compared to other treatments.
No provided label text includes GVHD-related mortality comparisons.
The other treatments included corticosteroids.
No provided label text includes comparator regimen details.
The other treatments included immunosuppressive agents.
No provided label text includes comparator regimen details.
Azacitidine is generally well-tolerated.
No provided 6 ADVERSE REACTIONS or Warnings/precautions text supports this general tolerability characterization.
Common side effects of azacitidine include fatigue.
No provided adverse reaction list/text containing fatigue was supplied.
Long-term safety and tolerability of azacitidine in the context of GVHD are still being investigated.
No provided label text addresses GVHD long-term safety/tolerability or investigation status.
Azacitidine is not approved for the treatment of GVHD.
Because the 1 INDICATIONS AND USAGE section was not provided, non-approval for GVHD cannot be verified from the supplied label text.
The patent for azacitidine's use in GVHD is still pending.
Patent status is not supported by the provided label sections.
The pending patent may impact azacitidine's availability for the GVHD indication.
Availability/market impact of patents is not supported by the provided label sections.
Contradictions
Low
AI Statement
Common side effects of azacitidine include nausea.
Label Reference
10 OVERDOSAGE (nausea mentioned only in overdose context) vs absence of 'common side effects' support in the provided excerpts.
Low
AI Statement
Common side effects of azacitidine include diarrhea.
Label Reference
10 OVERDOSAGE (diarrhea mentioned only in overdose context) vs absence of 'common side effects' support in the provided excerpts.
Important Omissions
Any label-supported dosage and administration details (e.g., dosing regimen, dose modifications, renal/hepatic adjustments) were not addressed in the AI claims set; therefore adherence to dosing safety requirements cannot be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims involve off-label-like GVHD outcomes and patient-safety-relevant tolerability characterization without label support, and adverse effect claims labeled as 'common' appear derived from overdose context rather than the adverse reactions section.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
Multiple key claims about indications, GVHD outcomes, and tolerability/side-effect prevalence are not verifiable against the provided label excerpts, and 'common side effects' are misrepresented using overdose wording.
Suggested Improvement
Restrict claims to statements directly supported by provided label sections (e.g., 12.1 excerpt). For indications and clinical outcomes, require and cite the actual 1 INDICATIONS AND USAGE and 14 CLINICAL STUDIES text. For adverse reactions, use the 6 ADVERSE REACTIONS section rather than 10 OVERDOSAGE to support 'common' side effects language.